Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New data examines effect of inhaled corticosteroids (ICS) on survival in patients with COPD

07.11.2002


New data examines effect of inhaled corticosteroids (ICS) on survival in patients with chronic obstructive pulmonary disease (COPD)

The findings of a retrospective database study examining the effect of inhaled corticosteroids (ICS) on survival in COPD patients1 were presented today at the American College of Chest Physicians CHEST 2002 Annual Conference in San Diego.

The investigators identified male and female patients, ages 40 and older, who were enrolled in the Lovelace and Kaiser Permanente-Georgia health plans during 1995 to 2000 and who had a diagnosis of COPD. In total, 1,685 patients were identified: the ’exposed groups’ consisted of patients who had 90 days or more use of ICS (n= 786), ICS plus salmeterol (n=332) or salmeterol without ICS (n=170); the reference, or ’unexposed,’ group (n=397) were patients who had not used ICS or a long-acting beta2-agonist but had been exposed to another respiratory drug for 90 days or more.



During the study period, 28 percent of patients in the unexposed group died compared to 14 percent of patients who had been exposed to ICS and/or salmeterol. In a statistical model that controlled for age, sex, comorbid conditions, COPD severity, and asthma status and severity, exposure to either ICS (Hazard Ratio [HR] 0.59, 95% Confidence Interval [CI]: 0.46, 0.78) or salmeterol (Hazard Ratio [HR] 0.55, 95% Confidence Interval [CI]: 0.34, 0.89) were associated with a decreased risk of death. In addition, exposure to ICS plus salmeterol also reduced the risk of death (HR 0.34, 95% CI: 0.21, 0.56). In a sensitivity analysis including only those COPD patients without a history of asthma (n=840), the reduction in risk of death associated with the use of ICS plus salmeterol remained significant (HR 0.35, 95% CI: 0.17, 0.71). Use of inhaled corticosteroids was associated with longer survival in COPD patients, independent of an asthma diagnosis, age, gender, or COPD severity.

According to the CDC, approximately 24 million Americans have evidence of impaired lung function consistent with a diagnosis of COPD, the fourth leading cause of death in the US. 2 In 2000, there were 119,052 deaths from COPD. 2

COPD is a multi-component disease that includes airway inflammation, bronchoconstriction and structural changes that result in airflow obstruction. These components contribute to complex changes in lung function, symptoms and exacerbations, which affect health status and ultimately survival.

No drug has been prospectively shown to reduce mortality in COPD. It is important to note that no inhaled corticosteroid alone, or combined with a long-acting bronchodilator, is currently approved for the treatment of COPD in the US.

Serevent DiskusÒ (salmeterol inhalation powder) should be used with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrthymias, and hypertension, and in patients with convulsive disorders or thytotoxicosis. Some patients may experience an increase in blood pressure or heart rate. Salmeterol should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants.


Contact Robin Gaitens at 919-483-2839 for complete prescribing information for Serevent Diskus.

Sources

1. Mapel D, Roblin D, Hurley J, Davis KJ, Schreiner R, Roberts M, Frost F. Survival of COPD patients exposed to inhaled corticosteroids. Chest 2002;122(4 Suppl):74S.

2. "Chronic Obstructive Pulmonary Disease Surveillance – United States, 1971-2000," Morbidity and Mortality Weekly Report, vol. 51; No. SS-6; August 2, 2002.


Robin Gaitens | EurekAlert!

More articles from Health and Medicine:

nachricht Nanoparticles as a Solution against Antibiotic Resistance?
15.12.2017 | Friedrich-Schiller-Universität Jena

nachricht Plasmonic biosensors enable development of new easy-to-use health tests
14.12.2017 | Aalto University

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: First-of-its-kind chemical oscillator offers new level of molecular control

DNA molecules that follow specific instructions could offer more precise molecular control of synthetic chemical systems, a discovery that opens the door for engineers to create molecular machines with new and complex behaviors.

Researchers have created chemical amplifiers and a chemical oscillator using a systematic method that has the potential to embed sophisticated circuit...

Im Focus: Long-lived storage of a photonic qubit for worldwide teleportation

MPQ scientists achieve long storage times for photonic quantum bits which break the lower bound for direct teleportation in a global quantum network.

Concerning the development of quantum memories for the realization of global quantum networks, scientists of the Quantum Dynamics Division led by Professor...

Im Focus: Electromagnetic water cloak eliminates drag and wake

Detailed calculations show water cloaks are feasible with today's technology

Researchers have developed a water cloaking concept based on electromagnetic forces that could eliminate an object's wake, greatly reducing its drag while...

Im Focus: Scientists channel graphene to understand filtration and ion transport into cells

Tiny pores at a cell's entryway act as miniature bouncers, letting in some electrically charged atoms--ions--but blocking others. Operating as exquisitely sensitive filters, these "ion channels" play a critical role in biological functions such as muscle contraction and the firing of brain cells.

To rapidly transport the right ions through the cell membrane, the tiny channels rely on a complex interplay between the ions and surrounding molecules,...

Im Focus: Towards data storage at the single molecule level

The miniaturization of the current technology of storage media is hindered by fundamental limits of quantum mechanics. A new approach consists in using so-called spin-crossover molecules as the smallest possible storage unit. Similar to normal hard drives, these special molecules can save information via their magnetic state. A research team from Kiel University has now managed to successfully place a new class of spin-crossover molecules onto a surface and to improve the molecule’s storage capacity. The storage density of conventional hard drives could therefore theoretically be increased by more than one hundred fold. The study has been published in the scientific journal Nano Letters.

Over the past few years, the building blocks of storage media have gotten ever smaller. But further miniaturization of the current technology is hindered by...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

See, understand and experience the work of the future

11.12.2017 | Event News

Innovative strategies to tackle parasitic worms

08.12.2017 | Event News

AKL’18: The opportunities and challenges of digitalization in the laser industry

07.12.2017 | Event News

 
Latest News

Engineers program tiny robots to move, think like insects

15.12.2017 | Power and Electrical Engineering

One in 5 materials chemistry papers may be wrong, study suggests

15.12.2017 | Materials Sciences

New antbird species discovered in Peru by LSU ornithologists

15.12.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>